The Drug Regulatory Authority of Pakistan (DRAP) has extended temporary appointments on several key positions for the fourth consecutive year. This ongoing practice raises concerns about the stability and continuity of leadership within the regulatory body responsible for overseeing pharmaceutical standards. Temporary appointments often lead to challenges in long-term policy implementation and institutional development.
DRAP plays a critical role in ensuring the safety, efficacy, and quality of medicines in Pakistan, making leadership consistency vital for effective regulation. The continuation of interim postings may affect the authority’s ability to enforce regulations and respond promptly to industry needs. Stakeholders in the healthcare and pharmaceutical sectors emphasize the importance of permanent appointments to strengthen governance and accountability.
In a significant development, the prolonged use of temporary appointments highlights broader issues within public sector management and recruitment processes. Addressing these concerns could improve DRAP’s operational efficiency and public trust. Meanwhile, industry experts advocate for transparent and merit-based selection to secure permanent leadership that can drive reforms and enhance regulatory frameworks.
Leave an opinion